Our Advisors



We recognize and value the importance leading experts across the Life Sciences space can bring to a development or repositioning plan.  Their insight and experience supports our goal to develop appropriate strategies and meet short and long term goals for our clients.








  • Diana Pliura, Ph.D. - Financial/Discovery/Pre-clinical/CMC

      Dr. Pliura has extensive biotechnology executive experience in advancing therapeutics products through all stages of development from discovery, target identification, lead optimization, preclinical development, manufacturing, technology transfer and early to late stage clinical development.  Dr. Pliura currently serves as the President in ALBRY Inc., which provides strategic advisory and management services to emerging life sciences initiatives, investors, technology transfer offices, and establishing companies undergoing transition.  Dr. Pliura was Executive Vice President at YM BioSciences Inc. (TSX: YM.TO; AMEX: YMI) from 2005 to 2008, where she was responsible for leading, aligning and integrating the clinical and commercial development for its product targeting the management of moderate to severe pain.  She was a co-founder, the President and Chief Executive Officer of DELEX Therapeutics Inc. ("DELEX") from 2001 to 2008, and a director of DELEX from 2001 to 2005, where she was responsible for securing equity financing, execution of milestones, strategic planning including leading to the acquisition of DELEX by YM BioSciences Inc. in 2005.  Dr. Pliura was the Company Creator (Biotechnology) of the Eastern Technology Seed Investment Fund (managed by Ventures West LLP) from 1998 to 2001.  Dr. Pliura founded and was the President of Diana H. Pliura & Associates in 1997.  She was Scientific Advisor at MDS Health Ventures and Vice President Research at Hemosol Inc. from 1992 to 1997.  She also held several research positions at Syntex ( Canada ) Research and National Research Council of Canada from 1980 to 1991. 

      Dr. Pliura was a Postdoctoral Fellow in the Chemistry Department of Harvard University.  Dr. Pliura received her Ph.D. degree in Chemistry from the University of Toronto and her Bachelors of Science (Honors) degree in Chemistry from McMaster University .  Dr. Pliura has 16 publications in peer reviewed journals and holds 7 issued U.S. patents and 3 pending U.S. patent applications with corresponding patents and patent applications in foreign jurisdictions.  


  • Terrance Sills, Ph.D. - Clinical/Regulatory/Biomarkers

    • Dr. Sills joined the Ontario Cancer Biomarker Network as Vice President to develop and grow the organization into a profitable business, and to work towards applying biomarkers and diagnostics to the development of personalized therapeutics, the medical model that will become prevalent in the 21st century.  In 2003, Dr. Sills co-founded AXON Clinical Research, which provided clinical research consulting services to the biotech sector.  At AXON, Dr. Sills worked on a number of development programs for small and mid-sized biotech companies.  In 1999, Dr. Sills took on the position of clinical research scientist at Boehringer Ingelheim, where he worked on a number of international drug-development programs (depression, stroke, female sexual dysfunction, and HIV/Aids).  Prior to this, Dr. Sills was a NARSAD-funded Research Scientist at the Centre for Addiction and Mental Health.

      Dr. Sills received his Ph.D. from the University of Toronto , and was a Fogarty Visiting Fellow at the National Institute of Mental Health in Bethesda, Maryland.


  • Shane Climie, Ph.D. - Pre-clinical/Technology Assessment

      Dr. Climie is a Principal with Popper and Company, which focuses on building life science organizations by meeting the needs of entrepreneurial, life science startups and the investors that support these early stage organizations. Popper and Co. provides expertise in the areas of business management, marketing strategy and technology or opportunity assessment. Dr. Climie has more than 20 years of R&D and business development experience in the life sciences and pharmaceutical industry. He has led research teams involved in all aspects of drug discovery and technology development, and has designed, negotiated and managed many R&D collaborations. He has extensive experience in technology evaluation, technology development and strategic planning. Prior to joining Popper and Co., Dr. Climie held several senior positions at Protana (formerly MDS Proteomics) including Senior Vice President of Science Strategy and Business Development, Senior Vice-President of Research Collaborations, and Vice-President of Proteomics and Business Development. From 1999 to 2000, Dr. Climie was co-founder, Vice-President and Chief Technology Officer of MDS Ocata. In 1999, Dr. Climie was a Visiting Research Scientist at the Samuel Lunenfeld Research Institute. From 1990 to 1999, Dr. Climie held several managerial positions at Allelix Biopharmaceuticals, Inc. (Now NPS Pharmaceuticals Inc., (Nasdaq:NPSP) including Principal Scientist.  

  • Dr. Climie did postdoctoral work at the University of California at San Francisco with Dr. Daniel Santi, and received a Ph.D. in medical biophysics from the University of Toronto and a B.Sc. in biology from the University of Waterloo.


About Us
c Our Team
c Preferred Partners
c Services
c Contact Us





Copyright © 2010 Concept 2 Clinic Inc.